Caribou Biosciences, Inc. Total Liabilities and Equity
Caribou Biosciences, Inc. (CRBU) had Total Liabilities and Equity of $142.77 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-13
- 2026-06-30: Liabilities and Equity $142.77M.
- 2026-03-31: Liabilities and Equity $149.00M.
- 2025-12-31: Liabilities and Equity $175.37M.
- 2025-09-30: Liabilities and Equity $194.98M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $142.77M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $149.00M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $175.37M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $194.98M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $220.90M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $273.66M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $313.31M 10-K · filed 2026-03-05 |
| 2024-09-30 | $344.33M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $372.94M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $406.82M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $432.21M 10-K · filed 2025-03-10 |
| 2023-09-30 | $457.52M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $349.65M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $347.46M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $373.76M 10-K · filed 2024-03-11 |
| 2022-09-30 | $398.82M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $421.37M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $446.00M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $442.36M 10-K · filed 2023-03-09 |
| 2021-09-30 | $461.96M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $158.40M 10-Q · filed 2021-09-02 |
| 2020-12-31 | $36.05M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |